Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Melanoma Drug Market
Interviewed Experts Lack Confidence in Malignant Melanoma Cancer
18-Sep-2008 -
Decision Resources finds that the malignant melanoma drug market, driven by the launch of emerging agents, will experience robust annual 12 percent growth through 2012 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The new Pharmacor report entitled Malignant ...
Germany
Italy
Japan
+4